Pay for Delay

Number 26852
Subject Drugs
Source PBSNewshour
State
Year 2014
Publication Date June 28, 2014
Summary Are generic drugs delayed to market by so-called “pay-for-delay” deals between brand and generic drug manufacturers? PBS NewsHour Weekend investigated these deals and other practices that opponents like the Federal Trade Commission say are meant to impede generic competition and protect profits. PBS NewsHour Weekend profiled Karen Winkler, a 46-year-old mother of three with Multiple Sclerosis. A deal was struck over her M.S. drug that opponents say delayed the generic to market. Then, the manufacturer raised the price to get patients to switch to its new extended-release version. Unable to afford it, Karen went off the drug until it went generic in 2012. PBS NewsHour Weekend shed light on complicated, secretive pharmaceutical deals rarely examined on national TV. These deals affect thousands of patients, but few know anything about them. And in cases like Winkler’s, they can have profound consequences.
Category Contest Entry
Pages
Keywords manufacturers; generic; brands; prescription; ftc; profits
Related Links
Related Video
Contest Questionnaires Only members can download contest entry questionnaires! Log in to get access.
Ordering info Want to place an order? Email us or call us at 573-882-3364 (Stories are only available to members of IRE. For membership information, please refer to our membership page)